Caristo Diagnostics has patented a test that analyses CT heart scans for signs of inflammation in the coronary arteries, which is a key process in the lead up to heart attacks. The company uses algorithms and artificial intelligence to detect biomarkers in a patient’s CT scan to predict the likelihood of that person having a heart attack. The results can be used by healthcare providers to suggest risk-reduction schemes and deploy appropriate treatments for the patient.
Dr David Schottlander is the Chief Technical Officer at Caristo, responsible for research, development and system operations. David joined the SME Leaders programme in 2020 and hopes to use the mentoring and training it provides to help maintain the high performance culture across the R&D team as it scales to support the company’s growth.
Caristo’s software will soon be launched in the UK and US. Once it gets regulatory approval, the company will market its software as a service, with healthcare providers sending patients’ CT scans for analysis. By the end of 2021, the clinical services should be in regular use by early adopters leading to mass market implementation.
Caristo’s innovation will help change medical intervention from being reactive to proactive. It will increase the opportunities to avoid fatal heart attacks and could save billions of pounds in cardiac care worldwide.
